16:42 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

BioCryst's oral HAE candidate reduces attack symptom severity in Phase II

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported data from 33 evaluable patients treated for a total of 95 acute attacks of hereditary angioedema (HAE) in the Phase II ZENITH-1 trial showing that a single 750 mg dose...
23:43 , May 31, 2018 |  BC Innovations  |  Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
02:03 , Jan 27, 2018 |  BioCentury  |  Finance

All together now

Promising proof-of-concept data from BioCryst Pharmaceuticals Inc. and a management team from Idera Pharmaceuticals Inc. with the requisite market know-how proved the right combination for a merger of two of the industry’s longest-standing independent small...
16:46 , Jan 26, 2018 |  BC Week In Review  |  Company News

BioCryst, Idera merging

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said Jan. 22 it will merge with Idera Pharmaceuticals Inc. (NASDAQ:IDRA) to form a company focused on rare diseases. The combined company will be renamed when the merger closes, which is...
00:17 , Jan 23, 2018 |  BC Extra  |  Company News

BioCryst, Idera merging

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said it will merge with Idera Pharmaceuticals Inc. (NASDAQ:IDRA) to form a company focused on rare diseases. The combined company will be renamed when the merger closes, which is expected in...
19:55 , Oct 13, 2017 |  BioCentury  |  Regulation

Expanding the HAE tool kit

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency. Two subcutaneous prophylactics that have completed Phase...
18:11 , Sep 15, 2017 |  BC Week In Review  |  Financial News

BioCryst and Portola price follow-ons

On Sept. 12, Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) priced follow-ons, raising over $420 million. Portola raised $349 million through the sale of 6.4 million shares at $55 in a bumped-up follow-on...
22:53 , Sep 13, 2017 |  BC Extra  |  Financial News

BioCryst, Portola price follow-ons

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) priced follow-ons late Tuesday, raising over $420 million. Portola raised $349 million through the sale of 6.4 million shares at $55 in a bumped-up follow-on underwritten...
17:16 , May 26, 2017 |  BC Week In Review  |  Clinical News

BioCryst's BCX7353 reduces HAE attacks in Phase II

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said 2 of 3 dose levels of oral BCX7353 significantly reduced mean hereditary angioedema (HAE) attacks during weeks 2 through 4 of the double-blind, international Phase II APeX-1 trial to prevent...
23:15 , May 25, 2017 |  BC Extra  |  Clinical News

Latest HAE analysis boosts BioCryst shares

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) jumped $1.60 (31%) to $6.73 after it said a second interim analysis showed two of three doses of BCX7353 significantly reduced hereditary angioedema attacks vs. placebo in the Phase II APeX-1...